The purpose of this study is to evaluate the efficacy and safety of FG-4592 in maintaining
and/or correcting hemoglobin (Hb) given to subjects with End Stage Renal Disease (ESRD) on
maintenance hemodialysis and receiving epoetin alfa.
Drug: Epoetin Alfa
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT01596855
Ages eligible for Study
18 Years to 75 Years
Genders eligible for Study
Accepts Healthy Volunteers
Subject has voluntarily signed and dated an informed consent form
Age 18 to 75 years
End-stage renal disease (ESRD) and receiving maintenance hemodialysis TIW for ≥4 months prior to Day 1
Hemoglobin (Hb) values in 4 screening visits and the mean Hb must be between 9.0 and 12.0 g/dL (inclusive), and the difference between them must be ≤1.5 g/dL.
Stable doses of IV or Subcutaneous injection of epoetin alfa, defined as follows:
Epoetin alfa dose range for 6 weeks prior to Day -7:
to 20,000 IU/week
Stable doses of epoetin alfa (i.e., the maximum epoetin alfa dose does not exceed 130% of the lowest dose of epoetin alfa taken in this period)
Complete Blood Count (CBC), Hematology, liver function blood tests within acceptable limits
Serum folate and vitamin B12 levels above the lower limit of normal (LLN)
Body weight: 40 to 100 kg (dry weight) inclusive
Body mass index (BMI): 16 to 38 kg/m2 inclusive
HD subjects: dialysis vascular access via native arteriovenous fistula or synthetic graft (not via catheter)
Anticipated change in hemodialysis prescription or access during the screening or dosing period of the study
Any clinically significant infection or evidence of an underlying infection such as a white blood cell count (WBC) > ULN during screening on two separate occasions,
Positive for any of the following: human immunodeficiency virus (HIV); hepatitis B surface antigen (HBsAg); anti-hepatitis C virus antibody (anti-HCV Ab)
History of chronic liver disease
New York Heart Association Class III or IV congestive heart failure
Chronic inflammatory disease other than glomerulonephritis that could impact erythropoiesis (e.g., systemic lupus erythematosis, rheumatoid arthritis, celiac disease) even if it is currently in remission
Active or chronic gastrointestinal bleeding, or a known coagulation disorder
Hemoglobinopathy (e.g., homozygous sickle-cell disease, thalassemia of all types, etc.)
Hematological disorders, including myelodysplastic syndrome, multiple myeloma, or pure red cell aplasia
History of hemosiderosis, hemochromatosis, polycystic kidney disease, or anephric
Active hemolysis or diagnosis of hemolytic syndrome
Known bone marrow fibrosis
Uncontrolled or symptomatic secondary hyperparathyroidism (PTH>600ng/L)
Any prior organ transplantation
Drug-treated gastroparesis, short-bowel syndrome, or any other gastrointestinal condition that may lead to reduced absorption of study drug
History of alcohol or drug abuse; or a positive drug screen for a substance that has not been prescribed for the subject
Prior treatment with FG-4592
Use of traditional Chinese medicines (TCM) during the screening visit to Day 1 or plans to use TCM during the study unless approved in advance by the Medical Monitor
All locations for NCT01596855
Peking Union Medical College Hospital
Peking University First Hospital
First Affiliated Hospital, Sun Yat-Sen University
Zhejiang University No 1. Hospital
Chang Zheng Hospital
ShenZhen People's Hospital
View full eligibility
Tris trial is registered with FDA with number: NCT01596855. The sponsor of the trial is FibroGen and it is looking for 96 volunteers for the current phase.
Official trial title: A Phase 2, Randomized, Open-Label Active-Comparator (Epoetin Alfa) Dose-Ranging Safety and Exploratory Efficacy Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis (HD)
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.